April 21, 2014
Kyowa Hakko Kirin announced on April 17 that it will terminate a license agreement with US-based Amgen Inc. for its humanized monoclonal antibody mogamulizumab. Under the license agreement inked in 2008 between the two companies, Kyowa Kirin granted Amgen exclusive...read more